#EULAR2023 #LB0005 Can we improve trial design of Bcell depletion in #SLE? Feasibility RCT of RTX in organ specific MSK showed: a)feasible to use ultrasound & clinical as endpoints, b)new tool LAMDA is responsive, c)potential worsening before later improvement with RTX @RheumNow https://t.co/kGDZ6EqLtq

Promising new therapies in SLE Dr. Yuz Yusof ( @Yuz6Yusof ) weighs in. The pharmacology treatment in SLE is a rapidly expanding field of research that provides excitement and optimism to both the patients and the clinicians. https://t.co/0G6EMYp2mb https://t.co/Yc31sR4fRE

• https://bit.ly/3N9L7di

Tune it at 1pm EST for RheumNow's daily #EULAR23 recaps. You can find us live on Twitter, YouTube and LinkedIn. https://t.co/t531csjXo8

#EULAR2023 #OP0290 Heterogeneity in #SLE is not only disease features but think of ANCESTRY. Data from BILAG-BR registry showed worse outcomes in people of Black and South Asian treated with either Rituximab or Belimumab (adjusted for deprivation index) @RheumNow https://t.co/bcdu9RIFSx

Predictors of first hospitalizations due to disease activity and infections in #lupus 1341 pts from multicenter latin american cohort. 33% with atleast one hospitalization, and 3/4th due to disease activity. @rheumnow #EULAR2023 abt#POS0169 https://t.co/vbJU4220is

Evaluation of diagnostic performance of ACR 1997, SLICC 2012 and EULAR /ACR diagnostic crieteria in childhood onset #SLE - SLICC highest sensitivity early in the disease, ACR1997 has the highest specificity both at diagnosis ans over time. @RheumNow #EULAR2023 abst#POS0136

#EULAR2023 #POS1124 My newly diagnosed patients & their carers often expressed heightened anxiety with poor quality web info about #SLE. Thank you @LupusEurope for this wonderful effort 👏. Available in most European languages too @RheumNow https://t.co/cr5Ls117xM